Wilson H. Miller
Affiliations: | McGill University, Montreal, QC, Canada |
Area:
Cell BiologyGoogle:
"Wilson Miller"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Marabelle A, Fakih M, Lopez J, et al. (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet. Oncology |
| Prabhu SA, Moussa O, Miller WH, et al. (2020) The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma. International Journal of Molecular Sciences. 21 |
| Yang W, Khoury E, Guo Q, et al. (2020) MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression. Oncogene |
| Chu QS, Jonker DJ, Provencher DM, et al. (2020) A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 38: 3581-3581 |
| Miller WH, Chu QS, Bouganim N, et al. (2020) A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 38: 3579-3579 |
| Dummer R, Sandhu SK, Miller WH, et al. (2020) A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). Journal of Clinical Oncology. 38: 10022-10022 |
| Maio M, Carlino M, Joshua A, et al. (2020) P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma Journal For Immunotherapy of Cancer. 8 |
| Chung HC, Piha-Paul SA, Lopez-Martin J, et al. (2019) Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Abdul Razak AR, Miller WH, Uy GL, et al. (2019) A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Investigational New Drugs |
| Esfahani K, Al-Aubodah TA, Thebault P, et al. (2019) Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nature Communications. 10: 4712 |